Emgality ‘CONQUER’s in late-stage migraine trial
Treatment with Emgality reduced monthly migraine headache days by 4.1 days.
Read More
Tag: CONQUER
- GSK wins US approval for ROS1 lung cancer therapy
- Lundbeck secures FDA Fast Track for narcolepsy drug
- R1 Therapeutics begins global phase 2b trial of AP306 for hyperphosphatemia
- Mission Therapeutics divests MTX652 to Dimerix in deal worth up to $292 million
- Nouscom to present re‑treatment data in Lynch Syndrome at ESMO 2026
